What are Natural Killer Cells and How Do They Fight Cancer?

Natural killer (NK) cells are white blood cells that serve as a part of the body’s first line of defense against infections and cancers. Along with T cells and B cells, NK cells have specialized roles as part of the immune system and have shown potential for being used in cancer immunotherapy. Their effectiveness is still being … Read more

What are Tyrosine Kinases?

Technically speaking, a tyrosine kinase is an enzyme that transfers a compound called a phosphate group from ATP — a molecule that stores energy — to a specific area on cell proteins. It helps transmit the signals that cause cells to grow and divide and to perform specific functions in the body such as burning … Read more

Specially Equipped Natural Killer Cells Show Promise Against Form of AML

CAR T cells’ superpower is to identify cancer-related targets on the surface of tumor cells and order an attack on those cells. But they lack anything resembling X-ray vision to detect nefarious protein targets within tumor cells. That shortfall has limited their effectiveness in diseases like acute myelogenous leukemia (AML), in which tumor cells display few surface … Read more

Advances in Myeloma, Breast Cancer, and Clinical Trials Equity: A Dana-Farber Research Update

Results of several phase 3 trials and dozens of other studies led by Dana-Farber researchers were presented online and in person June 3-7 at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), the world’s largest clinical cancer research meeting. Some of the research reports presented by Dana-Farber investigators include: Improved progression-free … Read more

Patient Participates in Clinical Trial Leading to Approval of CAR T-Cell Therapy for Form of Lymphoma

When lab tests confirmed that her non-Hodgkin lymphoma (NHL) had recurred after treatment, Ann Bonetti came to Dana-Farber expecting to hear she would need a stem cell transplant. When her oncologist told her about a clinical trial of a treatment that would turn her body’s own T cells into ace cancer fighters, she didn’t need … Read more

Junior Dana-Farber Analyst Named to Forbes Healthcare’s 30 under 30

At 28 years old, Dana-Farber bioinformatics analyst Carino Gurjao is already making a splash in the field of colorectal cancer research. He is coming off the back of a big year: The Paris-born researcher was named to Forbes Healthcare’s 2022 30 Under 30 list for his role in the Giannakis Lab at Dana-Farber, which identified … Read more

Addressing the Impact of Poverty on Childhood Cancer

Approximately one in three children in the United States lives in a low-income home. For childhood cancer patients, living in a low-income home can have a significant impact: Poverty and associated factors are linked to poorer outcomes, even at large academic medical centers like Dana-Farber, according to research by Kira Bona, MD, MPH, a pediatric … Read more

Mucosal Melanoma: What You Need to Know

While skin cancer is one of the most common types of cancer in the United States, melanoma is the least common type of skin cancer, accounting for less than 1 percent of skin cancer. Unlike most melanomas appearing on visible areas on the skin, mucosal melanoma occurs on the mucus membranes, or moist surfaces, of … Read more

Director of the Lynch Syndrome Center Shares his Personal Connection to Lynch Syndrome

Because of his adopted family’s cancer history, the director of Dana-Farber’s Lynch Syndrome Center, Matt Yurgelun, MD, is uniquely invested in helping patients with Lynch syndrome — a common and often under-diagnosed inherited condition. Eight of the 13 in his grandfather’s generation ultimately developed some form of cancer, and it wasn’t until later that Matt … Read more

How Does Cancer Start?

Every cancer starts with a mistake deep inside the nucleus of a single cell, where DNA is stored. Abnormalities in DNA can be inherited from one’s parents or can occur because of exposure to harmful substances in the environment such as chemicals in tobacco, ultraviolet radiation from the sun, and perhaps, chemicals in our diet. … Read more

Venetoclax Added to Chemotherapy Improves Outcomes in Type of Leukemia

Adding the BCL-2 inhibitor drug venetoclax to a combination chemotherapy regimen significantly improved outcomes in Richter’s syndrome, a rare but deadly complication that develops in some patients with chronic lymphocytic leukemia (CLL), according to a study led by Dana-Farber investigators. The addition of the targeted drug venetoclax to a chemo regimen called R-EPOCH yielded the … Read more

Anti-Microbial Drug Targets Key Driver of Chronic Lymphocytic Leukemia

Dana-Farber scientists have found that a generic anti-microbial drug can block a key molecular driver of chronic lymphocytic leukemia (CLL) cells, and when tested in a small clinical trial of advanced CLL patients who had relapsed, the drug slowed disease progression in half of them. The drug, pyrimethamine, achieved stable disease in eight of the … Read more

What is Ureteral Cancer?

Ureteral cancer is a type of cancer that grows in the ureter, or the two thin tubes that connect the kidneys to the bladder. It is uncommon compared with other cancers. What are the ureters? Kidneys make urine by filtering waste and extra water from blood. The urine travels from the kidneys to the bladder … Read more